STOCK TITAN

Clover Health (NASDAQ: CLOV) exec sells 7,289 shares under 10b5-1 plan

(Neutral)
(Negative)
Form Type
4

Rhea-AI Filing Summary

Clover Health Investments executive Jamie L. Reynoso, CEO of Medicare Advantage, reported an open-market sale of Class A Common Stock. Reynoso sold 7,289 shares at a weighted average price of $4.91 per share under a pre-arranged Rule 10b5-1 trading plan. After this transaction, Reynoso directly holds 2,849,921 shares, so the sale represents a small portion of her overall position.

Positive

  • None.

Negative

  • None.
Insider Reynoso Jamie L.
Role CEO, Medicare Advantage
Sold 7,289 shs ($36K)
Type Security Shares Price Value
Sale Class A Common Stock 7,289 $4.91 $36K
Holdings After Transaction: Class A Common Stock — 2,849,921 shares (Direct)
Footnotes (1)
  1. F1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.79 to $5.15, inclusive. The Reporting Person undertakes to provide to the SEC staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Remarks:
Shares sold 7,289 shares Open-market sale of Class A Common Stock
Weighted average sale price $4.91 per share Reported sale price for the transaction
Post-transaction holdings 2,849,921 shares Shares held directly after the sale
Transaction date June 11, 2026 Date of reported open-market sale
Trading plan adoption date March 12, 2026 Adoption date of Rule 10b5-1 trading plan
Price range of trades $4.79–$5.15 per share Range of individual sale prices
Rule 10b5-1 trading plan regulatory
"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Class A Common Stock financial
"security_title: Class A Common Stock"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did CLOV executive Jamie Reynoso report on this Form 4?

Jamie L. Reynoso reported selling 7,289 shares of Clover Health Class A Common Stock. The shares were sold in an open-market transaction at a weighted average price of $4.91 per share, according to the Form 4 disclosure and its accompanying footnote.

Was Jamie Reynoso’s CLOV stock sale made under a Rule 10b5-1 plan?

Yes. The Form 4 states the sale was effected under a Rule 10b5-1 trading plan. The plan was adopted on March 12, 2026, indicating the transaction was pre-scheduled rather than a discretionary trade based on short-term market conditions.

How many CLOV shares does Jamie Reynoso hold after this reported sale?

Following the reported sale, Jamie L. Reynoso directly holds 2,849,921 shares of Clover Health Class A Common Stock. This context shows the 7,289 shares sold are a small fraction of her total direct ownership position in the company.

What price range were Jamie Reynoso’s CLOV shares sold at in this transaction?

The weighted average sale price was $4.91 per share, with individual trades executed between $4.79 and $5.15. The Form 4 notes the insider will provide full price breakdowns for each trade upon request to regulators, the issuer, or security holders.

What role does Jamie Reynoso hold at Clover Health (CLOV)?

Jamie L. Reynoso is identified as an officer of Clover Health, serving as CEO, Medicare Advantage. This title indicates an executive leadership position focused on the company’s Medicare Advantage operations, as disclosed in the Form 4 reporting the share sale.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Reynoso Jamie L.

(Last)(First)(Middle)
C/O CLOVER HEALTH INVESTMENTS, CORP.
NOT APPLICABLE

(Street)
WILMINGTON DELAWARE 19801

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
CLOVER HEALTH INVESTMENTS, CORP. /DE [ CLOV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CEO, Medicare Advantage
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Common Stock06/11/2026S7,289(1)D$4.912,849,921D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.79 to $5.15, inclusive. The Reporting Person undertakes to provide to the SEC staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Remarks:
Remarks:
/s/Peter J. Rivas as attorney-in-fact for Jamie L. Reynoso06/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)